Take a trial of Australasia to unlock this pageFind out more
© Stockopedia 24th February, 2017

Regeneus

RGS A$0.15 0.0  3.5%
4:13am

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
12m Forecast Rolling
PE Ratio (ttm) 10.0
PEG Ratio (ttm)
EPS Growth (ttm) %
Dividend Yield (ttm) %
Valuation (ttm)
Price to Book Value 3.65
Price to Tang. Book
Price to Free Cashflow
Price to Sales
EV to EBITDA
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Jun 2011 2012 2013 2014 2015 2016 TTM 2017E 2018E CAGR / Avg
Revenue A$m
Operating Profit A$m
Net Profit A$m
EPS Reported AUD¢
EPS Normalised AUD¢
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps AUD¢
Capex ps AUD¢
Free Cashflow ps AUD¢
Dividends
Dividend ps AUD¢
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc A$m
Working Capital A$m
Net Fixed Assets A$m
Net Debt A$m
Book Value A$m
Average Shares m
Book Value ps AUD¢ -7.7%

FINANCIAL BRIEF: For the six months ended 31 December 2016, Regeneus Ltd revenues increased from A$881K to A$8.2M. Net income totaled A$3.8M vs. loss of A$3.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Selling Expenses decrease of 55% to A$111K (expense), Research and development expenses decrease of 5% to A$1.8M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
A+
A+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Jun 2017
30th Jun 2018

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (A$) (¢) (¢) (A$) (¢) (¢)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Regeneus
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Edison Investment Research Dennis Hulme , and 1 unnamed other

Profile Summary

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Directors: John Martin (CEO) , John Bird (CFO) , Graham Vesey (CSO) , Sandra McIntosh (DHR) , Charlotte Morgan (OTH) , Duncan Thomson (OTH) , Roger Aston (NEC) , Barry Sechos (NED) , Glen Richards (NID) ,

No. of Employees: n/a No. of Shareholders: n/a


Last Annual June 30th, 2016
Last Interim December 31st, 2016
Incorporated August 14, 2007
Public Since September 18, 2013
Shares in Issue 208,885,143
Free Float 131.6m (63.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Eligible for an ISA? a SIPP?

RGS Share Price Performance RGSQuote
A$0.15
0.0  3.5%
Traded 4:13am · Minimum 15 min delayed · NMS:


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2017.


Should you buy RGS

Access RGS Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder